Sonia Gran

Sonia Gran

Auto-generated profile, based on publicly available information

Sonia Gran

Centre of Evidence Based Dermatology, School of Medicine, University of Nottingham , Nottingham

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
LHL.M. Howells
L.M. Howells
JCJ.R. Chalmers
J.R. Chalmers
SGS. Gran
S. Gran
AAA. Ahmed
A. Ahmed
CAC. Apfelbacher
C. Apfelbacher
KTK.S. Thomas
K.S. Thomas
Eczema control has been identified as an important outcome by key stakeholders in eczema research (including patients, carers, healthcare professionals and researchers) but no validated instruments for the domain have been identified. To develop a measurement instrument to capture a patient's perspective of eczema control that is suitable for use in eczema clinical trials. Best practice for the development of a patient-reported outcome was followed. A mixed-methods approach was used to develop and refine a conceptual framework, generate, refine and select items and to test the distribution and construct validity of the final scale. The mixed-methods approach involved expert panel meetings (including patient representatives, healthcare professionals and methodologists), and data collection using a focus group, cognitive interviews and an online survey with people with eczema and caregivers. Multivariable linear regression was used in the item selection process. Fourteen expert panel members co-produced the instrument, with input from people with eczema and caregivers via a focus group (n = 6), cognitive interviews (n = 13) and an online survey (n = 330). The resulting instrument, Recap of atopic eczema (RECAP), is a seven-item questionnaire that captures eczema control via self or caregiver report. The development process aimed to ensure good content validity and feasibility. Initial testing suggested no floor or ceiling effects and good construct validity. Hypothesized correlation with the Patient-Oriented Eczema Measure was confirmed [r(258) = 0·83, P < 0·001]. RECAP has the potential to improve reporting of eczema control in research and clinical practice. Further exploration of measurement properties is required. What's already known about this topic? Eczema control has been identified as an important outcome by key stakeholders in eczema research (including patients, carers, healthcare professionals and researchers). Qualitative studies suggest eczema control is a multifaceted and individual experience and no instrument has been identified that captures eczema control in this way. What does this study add? We have developed Recap of atopic eczema (RECAP), a seven-item questionnaire to capture the experience of eczema control in all ages and eczema severities; there are two versions: a self-reported version for adults and older children with eczema, and a caregiver-reported version for younger children with eczema. Designed with input from people with eczema, caregivers and healthcare professionals to ensure good content validity. Initial testing of score distributions and construct validity suggests good measurement properties. What are the clinical implications of the work? The RECAP instrument is appropriate and feasible for measuring eczema control in clinical trials and may also be useful in routine practice.

9 March 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
MPM.S.M. Persson
M.S.M. Persson
KHK.E. Harman
K.E. Harman
YVY. Vinogradova
Y. Vinogradova
SLS.M. Langan
S.M. Langan
JHJ. Hippisley‐Cox
J. Hippisley‐Cox
SGS. Gran
S. Gran
Background A rising incidence and high mortality were found for bullous pemphigoid over a decade ago in the UK. Updated estimates of its epidemiology are required to understand the healthcare needs of an ageing population. Objectives To determine the incidence, prevalence, and mortality rates of bullous pemphigoid in England from 1998 to 2017. Methods We conducted a cohort study of longitudinal electronic health records using the Clinical Practice Research Datalink and linked Hospital Episode Statistics. Incidence was calculated per 100,000 person‐years and annual point prevalence per 100,000 people. Multivariable analysis was used to determine incidence rate ratios by sociodemographic factors. Mortality was examined in an age‐, sex‐, and practice‐matched cohort, using linked Office of National Statistics death records. Hazard ratios (HRs) were stratified by matched set. Results The incidence was 7.63 (95%CI 7.35 to 7.93)/100,000 person‐years and rose with increasing age, particularly for elderly men. The annual increase in incidence was 0.9% (95%CI 0.2 to 1.7). The prevalence almost doubled over the observation period, reaching 47.99 (95%CI 43.09 to 53.49)/100,000 people and 141.24 (95%CI 125.55 to 158.87)/100,000 people over the age of 60. The risk of all‐cause mortality was highest in the two years after diagnosis (HR 2.96; 95%CI 2.68 to 3.26), and remained raised thereafter (HR 1.54; 95%CI 1.36 to 1.74). Conclusions We report a modest increase in the incidence rate of bullous pemphigoid, but show that the burden of disease in the elderly population is considerable. Mortality is high, particularly in the first two years after diagnosis.

4 September 2021 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MPM.S.M. Persson
M.S.M. Persson
NBN. Begum
N. Begum
MGM.J. Grainge
M.J. Grainge
KHK.E. Harman
K.E. Harman
DGD. Grindlay
D. Grindlay
SGS. Gran
S. Gran

1 April 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
YAYuki M.F. Andersen
Yuki M.F. Andersen
AEAlexander Egeberg
Alexander Egeberg
LBLu Ban
Lu Ban
SGSonia Gran
Sonia Gran
HWHywel C. Williams
Hywel C. Williams
JTJacob P. Thyssen
Jacob P. Thyssen
OBJECTIVE: Topical corticosteroids (CSs) are commonly used to treat inflammatory skin conditions including eczema and psoriasis. Although topical CS package inserts describe hyperglycemia and glycosuria as adverse drug reactions, it is unclear whether topical CS use in real life is also associated with an increased risk of type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Two matched case-control studies and one cohort study were conducted using routinely collected health care data from Denmark and the U.K. A total of 115,218 and 54,944 adults were identified as case subjects with new-onset T2D in the Danish and U.K. case-control study, respectively. For the Danish cohort study, 2,689,473 adults were included. The main exposure was topical CSs, and the outcome was incident T2D. RESULTS: Topical CS was significantly associated with T2D in the Danish (adjusted odds ratio [OR] 1.25 [95% CI 1.23–1.28]) and U.K. (adjusted OR 1.27 [95% CI 1.23–1.31]) case-control studies. Individuals who were exposed to topical CSs had significantly increased risk of incident T2D (adjusted hazard ratio 1.27 [95% CI 1.26–1.29]). We observed significant dose-response relationships between T2D and increasing potency of topical CSs in the two Danish studies. The results were consistent across all sensitivity analyses. CONCLUSIONS: We found a positive association between topical CS prescribing and incident T2D in Danish and U.K. adult populations. Clinicians should be cognizant of possible diabetogenic effects of potent topical CSs.

5 May 2021 in Skin Health and Disease
Verified
Journal Article
Open access
PDF file
ACA. Cunliffe
A. Cunliffe
SGS. Gran
S. Gran
UAU. Ali
U. Ali
DGD. Grindlay
D. Grindlay
SLS. J. Lax
S. J. Lax
EBE. Burden-Teh
E. Burden-Teh
Importance: Previous studies report both coexistence and mutual exclusivity of atopic eczema (AE) and psoriasis, but these have not been appraised systematically. Knowledge of such disease association throws light on disease mechanisms and may influence therapeutic choices. Objective: To summarise evidence for AE and psoriasis occurring in the same person at the same point in time. Planned primary outcome was the incidence, prevalence or risk of psoriasis or eczema. Methods: Ovid MEDLINE and Ovid Embase were searched from inception to 1st February 2020. The search strategy was built around the key terms ‘atopic eczema’, ‘psoriasis’ and ‘co-existence’. Observational studies (cohort, case-control, cross-sectional and case-series) with a minimum of 10 consecutive patients were included. There were no restrictions on participants, geography or language. Studies were selected, data extracted and critically appraised by two independent reviewers. Data were extracted on the method of diagnosis: health professional (dermatologist, criteria, other), self-reported, not specified. Study quality was assessed using validated Joanna Brigg's Institute critical appraisal tools. A random-effects model was used to combine studies. The effect of study quality on the pooled estimate was investigated using stratification. Heterogeneity was explored by subgroup analysis. Results: This review included 31 studies and 20 523 individuals with psoriasis and 1 405 911 with AE. Eight studies reported the prevalence of AE in those with psoriasis and values ranged from 0.17% to 20%: the pooled prevalence was 2% (95% confidence interval [CI]: 1, 3). Seven studies reported the prevalence of psoriasis in those with AE and values ranged from 0.3% to 12.6%; the pooled prevalence was 2% (95% CI: 1, 3). Ten studies were assessed as low risk of bias. Geographical area, method of diagnosis, setting and whether the assessment of diagnosis was blinded, partly contributed to the heterogeneity. Conclusions: This review provides some evidence for the coexistence of AE and psoriasis. Clinicians should be aware of coexistence at diagnosis, when selecting therapies and when reviewing poor response to treatment.

29 June 2020 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ADA. Durack
A. Durack
SGS. Gran
S. Gran
MGM D Gardiner
M D Gardiner
AJA. Jain
A. Jain
ECemma craythorne
emma craythorne
BWB.E. Wright
B.E. Wright